Showing results (101-110 of 136) with videos related to
Sort By:
Pageof 14
Haematologica|February 13, 2008
Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomographyCaroline Bodet-Milin, Françoise Kraeber-Bodéré, Benoît Dupas, et al.Chemmedchem|February 7, 2023
Systematic Potency and Property Assessment of VHL Ligands and Implications on PROTAC DesignJohannes Krieger, Fiona J Sorrell, Ansgar A Wegener, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2005
Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy resultsTorsten Liersch, Johannes Meller, Bettina Kulle, et al.European Journal of Haematology|August 10, 2013
BCR-ABL1 molecular remission after 90Y-epratuzumab tetraxetan radioimmunotherapy in CD22+ Ph+ B-ALL: proof of principlePatrice Chevallier, Caroline Bodet-Milin, Nelly Robillard, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 30, 2011
Treatment of advanced pancreatic carcinoma with 90Y-Clivatuzumab Tetraxetan: a phase I single-dose escalation trialSeza A Gulec, Steven J Cohen, Kenneth L Pennington, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II resultsFranck Morschhauser, John P Leonard, Luis Fayad, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2003
Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphomaJohn P Leonard, Morton Coleman, Jamie C Ketas, et al.The Review of Scientific Instruments|April 24, 2024
Modular slot-die coater for in situ grazing-incidence x-ray scattering experiments on thin filmsManuel A Reus, Thomas Baier, Christoph G Lindenmeir, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2008
Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot StudyElizabeth A Raetz, Mitchell S Cairo, Michael J Borowitz, et al.Rheumatology (Oxford, England)|April 2, 2013
Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-upDaniel J Wallace, Caroline Gordon, Vibeke Strand, et al.Pageof 14